Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon α-2b for MRD-Positive Acute Leukemia Post-HSCT
NCT02185261Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2014
- Primary completion
- Jun 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of interferon alfa-2b in acute myeloid leukemia (AML), sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
interferon alfa-2b
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02185261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02185261.